Preprint · CC-BY
via OpenAlex
Alpha-Synuclein and synuceinopathies as related to Parkinson's disease
BIBSYS Brage (BIBSYS (Norway)) · 2017
Abstract
Parkinson’s disease (PD) is a chronic, progressive, complex, age-related and movement neurodegenerative disorder, caused by the loss of dopaminergic neurons in a small portion of cells within the mid brain known as the substantia nigra, with its actual etiology undiscovered. Alpha-Synuclein (a-Syn), a minute soluble protein that is primarily expressed at the presynaptic terminal or regions of the central nervous system with a yet unknown function is termed the central or key component to the pathogenesis of this disorder. Thus, Parkinson’s disease is the most commonly diagnosed and observed synucleinopathies. Alpha-Synucleinopathies are neurodegenerative disorders featured by the aberrant accretion or deposition of aggregates of alpha-synuclein in the neurons, glial cells or nerve fibres. There are three main types of synucleinopathies; Parkinson’s disease (PD), Dementia with Lewy bodies (DLB) and Multiple system atrophy (MSA). Not minding the similarities in their progressions and expansion, there are pathological differences that are significant between multiple system atrophy and Lewy body diseases, along with the cell types that are involved (in Parkinson’s disease, oligodendroglia in Multiple System Atrophy and Dementia with Lewy bodies) and the extent of neuronal loss in selected regions in Parkinson’s disease but spread all over the regions in Multiple System Atrophy.\nAlpha-synuclein, as abundantly found in various regions of the brain, having two intimately related homologs; Beta-synuclein and Gamma-synuclein, was recognised as the dominant component of amyloid fibrils observed in Lewy bodies and Lewy neurites which are the diagnostic hallmark of Parkinson’s disease. Aggregation of alpha-Synuclein is assumed to be the key or major event in the pathogenesis of synucleinopathies. Although, several alpha-Synuclein reformations and modifications have been thought to be responsible for early steps of aggregation.\nIn this thesis work, I will be able to summarize and review the data so far available on Alpha-synuclein, its structure, aggregation and fibrillation, the modifications and synucleinopathies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- Canonical
- link ↗
- Fetched
- 2026-10-20 MST
Cite this
APA
Anyanwu, F.E. (2017). Alpha-Synuclein and synuceinopathies as related to Parkinson's disease. <em>BIBSYS Brage (BIBSYS (Norway))</em>. https://openalex.org/W2756666768
Vancouver
Anyanwu FE. Alpha-Synuclein and synuceinopathies as related to Parkinson's disease. BIBSYS Brage (BIBSYS (Norway)). 2017.
BibTeX
@unpublished{ferdinand2017AlphaS,
title = {Alpha-Synuclein and synuceinopathies as related to Parkinson's disease},
author = {Ferdinand Eziokwu Anyanwu},
journal = {BIBSYS Brage (BIBSYS (Norway))},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Molecular Neurodegeneration 2019
Open access · CC-BY
Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles
Molecular Neurodegeneration 2011
Open access · CC-BY
Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
Heliyon 2019
Open access · CC-BY
Alpha synuclein in hematopoiesis and immunity
Frontiers in Neurology 2022
Open access · CC-BY
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
Acta Neuropathologica Communications 2015
Open access · CC-BY
Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein
Lund University Publications (Lund University) 2018
Preprint